Studies have shown that the gut microbiome composition changes significantly during GLP-1 therapy, with an increase in beneficial bacteria like Akkermansia muciniphila (Zhang et al., 2018). However, rapid weight loss can also lead to reduced microbial diversity in the gut, potentially impacting metabolic health (Moschen et al., 2012).